Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Equity (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Return on Equity for 11 consecutive years, with 0.25% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity rose 75.0% year-over-year to 0.25%, compared with a TTM value of 0.25% through Sep 2025, up 75.0%, and an annual FY2024 reading of 1.33%, down 134.0% over the prior year.
  • Return on Equity was 0.25% for Q3 2025 at CytomX Therapeutics, down from 0.66% in the prior quarter.
  • Across five years, Return on Equity topped out at 7.75% in Q1 2022 and bottomed at 6.71% in Q4 2021.
  • Average Return on Equity over 5 years is 0.09%, with a median of 0.15% recorded in 2023.
  • The sharpest move saw Return on Equity surged 1084bps in 2022, then crashed -693bps in 2023.
  • Year by year, Return on Equity stood at 6.71% in 2021, then soared by 118bps to 1.19% in 2022, then tumbled by -99bps to 0.01% in 2023, then crashed by -23219bps to 2.67% in 2024, then surged by 109bps to 0.25% in 2025.
  • Business Quant data shows Return on Equity for CTMX at 0.25% in Q3 2025, 0.66% in Q2 2025, and 3.38% in Q1 2025.